The clinicopathological and prognostic impact of 14-3-3 sigma expression on vulvar squamous cell carcinomas

  • Zhihui Wang1, 2, 3,

    Affiliated with

    • Claes G Tropè3, 4,

      Affiliated with

      • Zhenhe Suo1, 3,

        Affiliated with

        • Gunhild Trøen1,

          Affiliated with

          • Guanrui Yang2, 5,

            Affiliated with

            • Jahn M Nesland1, 3 and

              Affiliated with

              • Ruth Holm1Email author

                Affiliated with

                BMC Cancer20088:308

                DOI: 10.1186/1471-2407-8-308

                Received: 04 July 2008

                Accepted: 24 October 2008

                Published: 24 October 2008

                Abstract

                Background

                14-3-3 sigma (σ) promotes G2/M cell cycle arrest by sequestering cyclin B1-CDC2 complex in cytoplasm. Down-regulation of 14-3-3σ, which has been demonstrated in various carcinomas, may contribute to malignant transformation. However, the exact role of 14-3-3σ in the pathogenesis of vulvar carcinoma is not fully characterized, and the prognostic impact of 14-3-3σ protein expression is still unknown.

                Methods

                We investigated the 14-3-3σ expression in a series of 302 vulvar squamous cell carcinomas using immunohistochemistry and its associations with clinicopathological factors and clinical outcome.

                Results

                In cytoplasm, nucleus and cytoplasm/nucleus of vulvar carcinomas high 14-3-3σ protein expression was found in 72%, 59% and 75% of the carcinomas, respectively, and low levels in 28%, 41% and 25% of the cases, respectively. High level of 14-3-3σ in cytoplasm, nucleus and cytoplasm/nucleus was significantly correlated to large tumor diameter (p = 0.001, p = 0.002 and p = 0.001, respectively) and deep invasion (p = 0.01, p = 0.001 and p = 0.007, respectively). Variations of 14-3-3σ protein expression were not associated to disease-specific survival.

                Conclusion

                Our results indicate that 14-3-3σ may be involved in the development of a subset of vulvar squamous cell carcinomas by down-regulation of 14-3-3σ protein. Neither cytoplasmic nor nuclear level of 14-3-3σ expression was associated with prognosis.

                Background

                Vulvar carcinoma represents 3–5% of all female genital cancer [1] and was previously considered a disease of elderly women. However, we see an increase in the incidence of vulvar carcinomas among younger women in recent years [2]. Considerable morbidity is often followed radical surgery, which has been the standard treatment [3]. Individualized therapy has been introduced to raise the quality of life for vulvar cancer patients [4]. Targeted therapy urge us to search for factors involved in tumorigenesis as well as identification of new tumor markers for therapy.

                In mammals, 14-3-3 proteins are composed of a highly conserved multigene family of small acidic proteins, including seven 14-3-3 isoforms (β, ε, γ, η, σ, τ, ζ) [5]. As a phosphoserine/phosphothreonine-binding protein, 14-3-3s bind to proteins within their RS X pS X P and R X (Y/F) X pS X P sequences (pS represents phosphoserine or phosphothreonine) [6] and thereby play an important role in various cellular processes such as altering enzymatic activity, subcellular localization, protein-protein interactions, dephosphorylation, and proteolysis of individual target proteins [79].

                14-3-3σ, also named stratiffin, is mostly expressed in human epithelial cells [8]. Responsive to DNA damage, 14-3-3σ expression is induced in a p53-dependent manner [1012]. 14-3-3σ sequesters cyclin B1-CDC2 complex in cytoplasm, and prevents its entry into nucleus resulting in G2/M cell cycle arrest [10, 12]. Furthermore, 14-3-3σ can link to CDK2 and CDK4 and block the cell cycle entry [13]. Thus, 14-3-3σ acts as a negative regulator of cell cycle progression and is linked to cancer [14].

                Epigenetic change in the 14-3-3σ gene by CpG hypermethylation followed by down-regulation of 14-3-3σ expression has been demonstrated in various carcinomas [1522]. Furthermore, in breast carcinoma [22], endometrial carcinoma [23] and colorectal carcinoma [24] 14-3-3σ expression was found to be associated with the patients' clinical outcome. In a previous study, including a limited number of vulvar carcinomas, appropriately 60% of the cases revealed CpG methylation in the 14-3-3σ gene [25]. However, the expression of the 14-3-3σ protein and its connection with prognosis has still not been reported in vulvar carcinoma patients. Thus, we intended to study the 14-3-3σ expression in a series of 302 vulvar squamous cell carcinomas in order to disclose the correlation between 14-3-3σ expression and its prognostic value.

                Methods

                Patient materials

                A retrospective study was performed, in which 302 patients with squamous cell carcinoma of vulvar underwent surgery at The Norwegian Radium Hospital in the period 1977–2006. Before surgery, radiotherapy was given to 9 (3%) of the patients, additionally, 3 (1%) of the patients received chemotherapy. Radical vulvectomy was performed on 201 (67%) of the patients. Postoperative irradiation was given to 63 (21%), chemotherapy to 3 (1%) and irradiation/chemotherapy to 4 (1%) of the patients. One hundred and eight (36%) patients suffered from a relapse. The median age at diagnosis was 74 years (range 35–96 years). All patients were followed until death or 31. December, 2006. One hundred and twenty patients (40%) died of vulvar cancer. The median follow-up time for all patients was 52 months (range 0.4–346 months), whereas the median follow-up time for patients alive at last observation was 131 months (range 11–346 months). All tumors were staged according to the International Federation of Gynecology and the Obstetrics (FIGO) classification [26]. The Regional Committee for Medical Research Ethics South of Norway (S-06012), The Social- and Health Directorate (04/2639 and 06/1478) and The Data Inspectorate (04/01043) approved the study.

                Histological specimens were reviewed by one of the authors (J.M.N.) who had no access to clinical information. The tumors were classified according to World Health Organization recommendations [27] and 284 (94%) were keratinizing/nonkeratinizing, 14 (5%) were basaloid and 4 (1%) were veruccoid. The primary tumors of the patients have previously been investigated for the expression of p53, p16, p21, p27, p14, and the cyclins A, D1, D3 and E and human papillomavirus (HPV) [2831]. Table 1 provides a detailed description of the tumor characteristics. As controls, samples of normal vulva were collected form 11 patients undergone surgery for benign gynecological diseases.
                Table 1

                14-3-3σ immunostaining in relation to clinicopathological variables

                Variables

                Total

                Cytoplasm

                Nucleus

                Cytoplasm and nucleus

                 

                n

                Low

                High

                (%)

                p 1

                Low

                High

                (%)

                p 1

                Low

                High

                (%)

                p 1

                Age

                    

                0.21

                   

                0.96

                   

                0.06

                   25–69

                121

                39

                82

                (68)

                 

                49

                72

                (60)

                 

                38

                83

                (69)

                 

                   70–84

                147

                34

                113

                (77)

                 

                62

                85

                (58)

                 

                28

                119

                (81)

                 

                   85+

                34

                11

                23

                (68)

                 

                14

                20

                (59)

                 

                10

                24

                (71)

                 

                FIGO

                    

                0.26

                   

                0.49

                   

                0.08

                   Ia

                11

                2

                9

                (82)

                 

                4

                7

                (64)

                 

                2

                9

                (82)

                 

                   Ib

                37

                16

                21

                (57)

                 

                19

                18

                (49)

                 

                16

                21

                (57)

                 

                   II

                110

                28

                82

                (75)

                 

                43

                67

                (61)

                 

                22

                88

                (80)

                 

                   III

                121

                32

                89

                (74)

                 

                46

                75

                (62)

                 

                30

                91

                (75)

                 

                   IV

                19

                5

                14

                (74)

                 

                10

                9

                (47)

                 

                5

                14

                (74)

                 

                   Not available

                4

                            

                Lymph node metastasis

                    

                0.42

                   

                0.97

                   

                0.54

                   None

                137

                41

                96

                (70)

                 

                55

                82

                (60)

                 

                36

                101

                (74)

                 

                   Unilateral

                76

                18

                58

                (76)

                 

                31

                45

                (59)

                 

                17

                59

                (78)

                 

                   Bilateral

                34

                12

                22

                (65)

                 

                13

                21

                (62)

                 

                11

                23

                (68)

                 

                   Not available

                55

                            

                Tumour diameter (cm)

                    

                0.001

                   

                0.002

                   

                0.001

                   0.3–2.5

                92

                34

                58

                (63)

                 

                50

                42

                (46)

                 

                33

                59

                (64)

                 

                   2.6–4.0

                94

                30

                64

                (68)

                 

                35

                59

                (63)

                 

                25

                69

                (73)

                 

                   4.1–20.0

                100

                14

                86

                (86)

                 

                30

                70

                (70)

                 

                12

                88

                (88)

                 

                   Not available

                16

                            

                Tumor differentiation

                    

                0.09

                   

                0.10

                   

                0.08

                   Well

                76

                27

                49

                (65)

                 

                39

                37

                (49)

                 

                25

                51

                (67)

                 

                   Moderate

                154

                43

                111

                (72)

                 

                61

                93

                (60)

                 

                39

                115

                (75)

                 

                   Poor

                72

                14

                58

                (81)

                 

                25

                47

                (65)

                 

                12

                60

                (83)

                 

                Depth of invasion (mm)

                    

                0.01

                   

                0.001

                   

                0.007

                   0.0–4.0

                80

                32

                48

                (60)

                 

                45

                35

                (44)

                 

                30

                50

                (63)

                 

                   4.1–8.0

                99

                24

                75

                (76)

                 

                38

                61

                (62)

                 

                21

                78

                (79)

                 

                   8.1–40.0

                112

                24

                88

                (79)

                 

                34

                78

                (70)

                 

                21

                91

                (81)

                 

                   Not available

                11

                            

                Infiltration of vessel

                    

                0.33

                   

                0.50

                   

                0.41

                   No

                233

                67

                166

                (71)

                 

                99

                134

                (58)

                 

                61

                172

                (74)

                 

                   Yes

                66

                15

                51

                (77)

                 

                25

                41

                (62)

                 

                14

                52

                (79)

                 

                   Not available

                3

                            

                p142

                    

                1.00

                   

                1.00

                   

                0.88

                   Low (-)

                135

                98

                37

                (27)

                 

                46

                89

                (66)

                 

                84

                51

                (38)

                 

                   High (+)

                77

                56

                21

                (27)

                 

                26

                51

                (66)

                 

                49

                28

                (36)

                 

                   Not available

                100

                            

                p162

                    

                0.63

                   

                0.88

                   

                0.15

                   Low (< 5%)

                148

                40

                108

                (73)

                 

                51

                97

                (66)

                 

                37

                111

                (75)

                 

                   High (≥ 5%)

                63

                15

                48

                (76)

                 

                21

                42

                (67)

                 

                10

                53

                (84)

                 

                   Not available

                91

                            

                p212

                    

                0.17

                   

                0.87

                   

                0.10

                   Low (-)

                122

                36

                86

                (71)

                 

                42

                80

                (66)

                 

                32

                90

                (74)

                 

                   High (+)

                90

                19

                71

                (79)

                 

                30

                60

                (67)

                 

                15

                75

                (84)

                 

                   Not available

                90

                            

                p272

                    

                0.18

                   

                0.56

                   

                0.19

                   Low (< 50%)

                164

                39

                125

                (76)

                 

                54

                110

                (67)

                 

                33

                131

                (80)

                 

                   High (≥ 50%)

                48

                16

                32

                (67)

                 

                18

                30

                (63)

                 

                14

                34

                (71)

                 

                   Not available

                90

                            

                p532

                    

                0.70

                   

                0.12

                   

                0.93

                   Low (< 5%)

                93

                25

                68

                (73)

                 

                26

                67

                (72)

                 

                20

                73

                (79)

                 

                   High (≥ 5%)

                118

                29

                89

                (75)

                 

                45

                73

                (62)

                 

                26

                92

                (78)

                 

                   Not available

                91

                            

                Cyclin A2

                    

                0.68

                   

                0.09

                   

                0.59

                   Low (< 5%)

                61

                17

                44

                (72)

                 

                26

                35

                (57)

                 

                15

                46

                (75)

                 

                   High (≥ 5%)

                151

                38

                113

                (75)

                 

                46

                105

                (70)

                 

                32

                119

                (79)

                 

                   Not available

                90

                            

                Cyclin D12

                    

                0.87

                   

                0.75

                   

                0.83

                   Low (-)

                156

                40

                116

                (74)

                 

                52

                104

                (67)

                 

                34

                122

                (78)

                 

                   High (+)

                56

                15

                41

                (73)

                 

                20

                36

                (64)

                 

                13

                43

                (77)

                 

                   Not available

                90

                            

                Cyclin D32

                    

                0.25

                   

                0.76

                   

                0.69

                   Low (< 50%)

                153

                43

                110

                (72)

                 

                51

                102

                (67)

                 

                35

                118

                (77)

                 

                   High (≥ 50%)

                59

                12

                47

                (80)

                 

                21

                38

                (64)

                 

                12

                47

                (80)

                 

                   Not available

                90

                            

                Cyclin E2

                    

                0.72

                   

                0.64

                   

                0.32

                   Low (< 50%)

                173

                44

                129

                (75)

                 

                60

                113

                (65)

                 

                36

                137

                (79)

                 

                   High (≥ 50%)

                39

                11

                28

                (72)

                 

                12

                27

                (69)

                 

                11

                28

                (72)

                 

                   Not available

                90

                            

                HPV2

                    

                0.87

                   

                0.47

                   

                0.98

                   Low (-)

                168

                44

                124

                (74)

                 

                57

                111

                (66)

                 

                39

                129

                (77)

                 

                   High (+)

                44

                11

                33

                (75)

                 

                15

                29

                (66)

                 

                8

                36

                (82)

                 

                   Not available

                90

                            

                1 Pearson chi-square2 In previous reports, p53, p16, p21, p27, p14, cyclin A, cyclin D1, cyclin D3, cyclin E and HPV have been studied [2831].

                Cell Line

                Human vulvar squamous cell carcinoma cell lines SW-954 (ATCC, Manassas, VA, U.S.A) and CAL-39 (DSMZ, Germany) were grown as monolayer cultures recommended by the suppliers. For RNA analysis, cells from monolayer culture were harvested by using 0.01 M EDTA solution and washed in PBS. For immunohistochemstry, cells were fixed in 4% formalin and embedded in paraffin.

                Immunohistochemical method

                Sections (4 μm) from formalin-fixed, paraffin-embedded tissue were processed for immunohistochemistry using the Dako EnVision™ + System, Peroxidase (DAB) (K4007, Dako Corporation, CA, U.S.A). Deparaffinized sections were microwaved in 10 mM citrate buffer pH 6.0 to unmask the epitopes and treated with 0.3% hydrogen peroxidase (H2O2) for 5 min to block endogenous peroxidase. Monoclonal 14-3-3σ antibody (clone 1433S01, 1:75, 2.7 μg IgG1/ml) from NeoMarkers, CA, U.S.A were applied on the sections for 30 min at room temperature. The primary antibody is highly specific to 14-3-3σ and shows no cross-reaction with other isoforms of 14-3-3 (information from NeoMarkers). Subsequently, the slides were incubated with horseradish peroxidase (HRP) labeled polymer conjugated goat-anti-mouse for 30 min, followed by incubation with 3'3-diaminobenzidine tetrahydrochloride (DAB) for 10 min. The sections were counterstained with hematoxylin, dehydrated and mounted in Diatex.

                Normal skin was included as positive control in all series. Negative controls included substitution of the monoclonal antibody with mouse myeloma protein of the same subclass and concentration as the monoclonal antibody. Both nuclear and cytoplasmic staining was considered positive. Immunostaining was scored on a 3 – tiered scale for both intensity (absent/weak, 1; moderate, 2; strong, 3) and extent of staining (percentage of positive tumor cells: < 10%, 1; 10–50%, 2; > 50%, 3). Scoring results of intensity and extent were multiplied to give a composite score ranging from 1 to 9 for each section. Protein expression in cytoplasm was defined as high when composite scores were ≥ 6, and low when composite scores were < 6, whereas, protein expression in nucleus were classified as high when any 14-3-3σ staining was observed in the tumor and low when no staining was seen. This is based on staining pattern observed in normal vulvar epithelium. We later verified all other cutoff values. Examination of immunostaining was performed by two independent observers (Z.W. and R.H.) with no knowledge of patient outcome. All discordant scores were reviewed until final agreement was obtained. Reproducibility in the semiquantitative scoring was controlled. The kappa values were 0.72 for both extra- and intra-observer variability when determined on a subset of 40 patients.

                Laser captured microdissection (LMC)

                Eleven vulvar carcinomas frozened at -70°C were selected for LMC and RNA isolation.

                First, 8 μm frozen sections were fixed in ethanol, stained with hematoxylin-eosin (HE), dehydrated in graded ethanol and zylene and air-dried for 5 min. Then, by using a PixCell laser capture microscope (Arctrurus Engineering Inc., Mountain View, CA), 30–200 pure tumor cells were captured on caps by focal melting of the membrane through laser activation. The LMC parameters were as follows, a laser power of 70–80 mW, laser pulse duration of 1.2–3.5 ms, and laser spot size of 7.5–15 μm in diameter. Finally, the caps with the selected cells were covered with lysis buffer in Eppendorf tubes and rotated several times for homogenization before RNA isolation.

                RNA isolation

                An Absolutely RNA™ Nanoprep Kit (Stratagene Inc. La Jolla, USA), which was special designed to purify RNA from 1 to 104 cells, was employed to extract and purify RNA from cells captured on caps by LCM. Total RNA and Protein Isolation Kit (Macherey-Nagel, Duren, Germany) was used to isolate total RNA form cell line SW-954 and CAL-39 as recommended by the manufacturer.

                RT-PCR

                Transcriptor First Stand cDNA Synthesis Kit (Roche Inc., Mannheim, Germany) was used to synthesis cDNA. The total reaction volume was 20 μl and the reaction systems were: (1) RNA from LMC tissues: 4 μl 5 × Transcriptor RT Reaction Buffer, 0.5 μl Protector Rnase Inhibitor, 0.5 μl Transcriptor Reverse Transcriptase, 2 μl dNTP Mix (PCR grade), 1 μl Anchored Oligo (dt)18 Primer, 2 μl Water (PCR Grade), and 10 μl RNA. (2) RNA form cell line: 4 μl 5 × Transcriptor RT Reaction Buffer, 0.5 μl Protector Rnase Inhibitor, 0.5 μl Transcriptor Reverse Transcriptase, 2 μl dNTP Mix (PCR grade), 1 μl Anchored Oligo (dt)18 Primer, 10 μl Water (PCR Grade), and 2 μl RNA. The reaction condition was: 65°C for 10 min for mixture of cDNA and primer pre-denaturation, followed by 55°C for 30 min for reverse transcription of RNA, ended by 85°C for 5 min for inaction of reverse transcriptase.

                Quantitative Real-Time PCR

                Five μl cDNA from LMC samples and 2 μl cDNA from cell lines were used as templates in subsequent Real-Time reaction performed on LightCycler 2.0 system (Roche Inc., Mannheim, Germany) using LightCycler® TaqMan® Master kit (Roche Inc., Mannheim, Germany) and gene specific Hydrolysis (TaqMan) Probes, according to the manufacturer's instruction. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as an internal control for relative gene expression quantification and for each gene amplification. Cp values (reading obtained at 530 nm) were normalized to the Cp of the GAPDH using the LightCycler analysis software. The following sets of primers were used to amplify gene products for Real-Time PCR reactions: GAPDH forward-5'-AGC CAC ATC GCT CAG ACA, reverse-5'-GCC CAA TAC GAC CAA ATC C; 14-3-3σ forward-5'-GAC ACA GAG TCC GGC ATT G, reverse-5'-ATG GCT CTG GGG ACA CAC.

                Statistical analyses

                The association between 14-3-3σ protein expression and clinicopathologic variables, and that between 14-3-3σ protein expression and 14-3-3σ mRNA expression levels were evaluated by the Person χ2 test. The Kaplan and Meier method and the log-rank test were used to estimate and compare survival rate. Disease-specific survival was defined as the interval between diagnosis and death due to vulvar cancer. A Cox proportional hazards regression model was used for multivariate evaluation of survival rates. A backward stepwise regression with a p = 0.05 in univariate analysis as the inclusion criterion was used. All calculation was performed using the SPSS 15.0 statistical software package (SPSS, Chicago, IL). Statistical significance was considered as p ≤ 0.05.

                Results

                14-3-3σ protein expression

                In normal vulvar epithelium, none of the 11 cases showed nuclear 14-3-3σ immunostaining. Nevertheless, high level of cytoplasmic staining (score ≥ 6) was present in 11/11 (100%) cases. The 14-3-3σ immunostaining was found in the basal, parabasal, middle and top layers of the vulvar epithelium (Figure 1a). In vulvar carcinomas, high 14-3-3σ expression (score ≥ 6) in cytoplasm was found in 218 (72%) cases and low levels in 84 (28%), whereas, high levels of nuclear immunostaining of 14-3-3σ (any positive nuclei) were observed in 177 (59%) cases, and low levels in 125 (41%). High 14-3-3σ expression (score ≥ 6) in cytoplasm/nuclei was found in 226 (75%) cases and low levels in 76 (25%) (Figure 1b and Table 2).
                http://static-content.springer.com/image/art%3A10.1186%2F1471-2407-8-308/MediaObjects/12885_2008_Article_1246_Fig1_HTML.jpg
                Figure 1

                Expression of 14-3-3σ protein. Expression of 14-3-3σ protein in normal vulvar epithelium (a), vulvar carcinoma (b), SW-954 cell line (c) and CAL-39 cell line (d).

                Table 2

                Immunostaining results for 14-3-3σ

                Score

                Cytoplasm

                Nucleus

                Cytoplasm and nucleus

                 

                n (%)

                n (%)

                n (%)

                0

                2 (0.7)

                125 (41.4)

                2 (0.7)

                1

                1 (0.3)

                0 (0.0)

                1 (0.3)

                2

                1 (0.3)

                16 (5.3)

                1 (0.3)

                3

                67 (22.2)

                76 (25.2)

                58 (19.2)

                4

                13 (4.3)

                28 (9.3)

                14 (4.6)

                6

                142 (47.0)

                50 (16.6)

                119 (39.4)

                9

                76 (25.2)

                7 (2.3)

                107 (35.4)

                Total

                302 (100.0)

                302 (100.0)

                302 (100.0)

                In the vulvar carcinoma cell lines SW-954 and CAL-39 high levels (score ≥ 6) of cytoplasmic 14-3-3σ immunostaining were observed (Figure 1c and 1d).

                14-3-3σ mRNA expression and association with 14-3-3σ protein levels

                Expression of 14-3-3σ mRNA was found in all laser-microdissection-captured vulvar carcinomas and in both vulvar carcinoma cell lines SW-954 and CAL-39. However, the mRNA expression levels were variable (Figure 2). No significant association was observed between levels of 14-3-3σ mRNA and 14-3-3σ protein expression in cytoplasm (p = 0.242), nucleus (p = 1.000) or cytoplasm/nucleus (p = 0.242) in vulvar carcinomas. Both cell lines showed low levels of 14-3-3σ mRNA expression and did not correlate to the high (score ≥ 6) 14-3-3σ protein expression.
                http://static-content.springer.com/image/art%3A10.1186%2F1471-2407-8-308/MediaObjects/12885_2008_Article_1246_Fig2_HTML.jpg
                Figure 2

                Expression of 14-3-3σ mRNA in vulvar carcinomas and vulvar cell lines. Expression of 14-3-3σ mRNA in vulvar carcinomas (no.1–11), vulvar carcinoma cell lines SW-954 (no.12) and CAL-39 (no.13).

                14-3-3σ immunostaining in relation to clinicopathological parameters and patients survival

                The levels of 14-3-3σ immunostaining in relation to clinicopathological parameters are shown in Table 1. High expression of 14-3-3σ in cytoplasm, nucleus and cytoplasm/nucleus were significantly correlated to large tumor diameter (p = 0.001, p = 0.002 and p = 0.001, respectively) and deep invasion (p = 0.01, p = 0.001 and p = 0.007, respectively). 14-3-3σ was neither associated to the cell cycle proteins p14, p16, p21, p27, p53 and cyclin A1, D1, D3 and E, nor to HPV.

                In univariate analysis, with the variables defined in Table 1, age (p = 0.002), tumor diameter (p < 0.001), depth of invasion (p = 0.007), lymph node metastasis (p < 0.001), FIGO (p < 0.001) and infiltration of vessel (p < 0.001) were correlated to disease-specific survival. There was no significant association between disease-specific survival and 14-3-3σ expression in cytoplasm (p = 0.23), nuclear (p = 0.51) and cytoplasm/nuclear (p = 0.21). In multivariate analysis, FIGO, lymph node metastasis, age and depth of invasion were of independent prognostic significance (Table 3).
                Table 3

                Relative risk (RR) of dying from vulvar cancer

                Variable

                Grouping

                Ratio of risk (RR)

                95% CI

                p

                FIGO

                1a vs 1b vs II vs III vs IV

                1.86

                1.18–2.9

                0.007

                Lymph nodes metastsis

                Absent vs Present

                1.49

                1.00–2.23

                0.05

                Age

                25–69 yrs vs 70–84 yrs vs = 85 yrs

                1.10

                1.00–1.04

                0.05

                Depth of invasion

                0.0–4.0 mm vs 4.1–8.0 mm vs 8.1–35.0 mm

                1.82

                1.13–2.94

                0.01

                Discussion

                In our study normal vulvar squamous epithelium showed high cytoplasmic positivity for 14-3-3σ protein in the whole layer, which is similar to the findings in normal squamous epithelium of skin, esophagus and cervix [32]. However, in normal tongue 14-3-3σ immunoreactivity was often weak in the basal layer compared to that of the middle and top layers [32]. One explanation for these different results may be that p63 is extensively present in low layer of epidermal tongue [33], and that ΔNp63 depress 14-3-3σ expression [34] by controlling the p53-binding site of 14-3-3σ. However, when keratinocytes become more differentiated, and less ΔNp63 is produced, 14-3-3σ expression resume.

                Mhawech et al [35] have studied the expression of 14-3-3σ protein in neoplastic tissues of urological and gynecological cancers. Positive 14-3-3σ protein expression was seen in urothelial bladder carcinoma (97.8%), squamous cell carcinoma of cervix (66.7%), endometrial adenocarcinoma (56.5%), prostatic adenocarcinoma (55.0%), renal papillary tumor (50%), ovarian adenocarcinoma (33.3%), and breast carcinoma (23.3%). In our study, positive 14-3-3σ staining was identified in cytoplasm and/or nucleus in 99.3% of vulvar carcinomas.

                Gasco et al [25] identified methylation within the 14-3-3σ gene in approximately 60% of vulvar carcinomas. However, in the present study low levels of 14-3-3σ protein was found in only 25% of vulvar carcinomas. We have identified 14-3-3σ methylation in 57/57 (100%) vulvar carcinomas and 5/5 (100%) normal blood samples, whereas the two vulvar squamous cell carcinoma cell lines SW-954 and CAL-39 were unmethylated for 14-3-3σ (unpublished data). 14-3-3σ methylation in all normal blood samples and vulvar carcinomas may be due to the normal lymphocytes in blood and the lymphocytes surrounding the epithelial tumors. Previously, Bhatia et al [36] have demonstrated 14-3-3σ gene to be methylated in normal lymphocytes. Therefore, methylation identified within 14-3-3σ gene in some of the vulvar carcinomas reported by Gasco et al [25] may be due to inflammatory cells surrounding cancer cells [37]. Despite this problem, the low level of 14-3-3σ protein expression in a relative high number of vulvar carcinomas indicates that loss of 14-3-3σ expression may be important in the pathogenesis of a subset of vulvar squamous cell carcinoma.

                Interestingly, we found different subcellular distribution of 14-3-3σ protein in cells in normal tissues and in cancer tissues. The high 14-3-3σ expression in cytoplasm but not in nucleus was found in all the 11 normal tissues, whereas, in vulvar carcinomas 72% and 59% of the cases had high expression of 14-3-3σ in cytoplasm and nucleus, respectively. Previously, Van Hermet and coworkers [38] showed that 14-3-3σ was mainly localized in the cytoplasm and only in lower levels present in the nucleus, which is consistent with subcellar distribution of the protein in normal vulvar cells. The cytoplasmic localization of 14-3-3σ protein in normal vulvar cells may prevent cyclin B1-CDC2 complex from entering the nucleus and initiate mitosis [14, 39]. In the present work we have found in vulvar carcinoma cells that more 14-3-3σ protein moved from cytoplasm to nucleus and stayed there. This might imply that 14-3-3σ have less power to sequester cyclin B1-CDC2 complex in cytoplasm by its nucleus translocation, as a result cell fails to be arrested at G2 checkpoint, but enters into cell division. [14] Nuclear location of 14-3-3σ protein may thus play a role in tumorigenesis of vulvar squamous cell carcinomas. However, we found that high expression of 14-3-3σ in cytoplasm as well as in nucleus was significantly correlated to large tumor diameter and deep of invasion. Furthermore, neither 14-3-3σ expression in cytoplasm nor in nucleus was significant associated with clinical outcome. These results may indicate that the cellular localization of 14-3-3σ is not important for the progression of vulvar carcinomas. However, we cannot exclude the possibility that nuclear localization of 14-3-3σ protein may be an early event in carcinogenesis of vulvar carcinomas. Further studies are needed to clarify the importance of 14-3-3σ nuclear localization in development of vulvar carcinomas.

                In our study, we found that high 14-3-3σ protein expression in cytoplasm, nuclear, and both cytoplasm/nuclear was significant correlated with large tumor diameter and deep invasion. This is in disagreement with the findings in colorectal carcinomas [24] and gastric carcinomas [40], where 14-3-3σ protein expression did not correlate with tumor size.

                For the first time, 14-3-3σ protein expression and its prognostic importance has been examined in vulvar squamous cell carcinomas. No significant association was found between disease-specific survival and 14-3-3σ expression, which was in line with the findings in breast carcinomas [22]. However, in breast carcinomas 14-3-3σ cytoplasmic subcellular localization showed a statistically significant correlation with survival in univariate analysis, but not in multivariate analysis [22]. Previously, loss of the 14-3-3σ protein expression was correlated with poor prognosis in epithelial ovarian cancer in univariate analysis, but not in multivariate analysis [41]. Patients with endometrial adenocarcinoma absence of 14-3-3σ protein expression had a shorter overall survival in multivariate analysis [23]. In contrast to these findings, Perathoner et al [24] found that in colorectal carcinoma patients increased expression of 14-3-3σ protein were associated with poor survival in multivariate analysis. Taken together, these studies indicate that the role of 14-3-3σ is cancer specific.

                In the present work, 14-3-3σ was not associated to p53 protein expression, which was similar to the findings in a variety of cancers from bladder, prostate, endometrium, ovarium, breast [37] and neuroendocrine lung tumors [21]. These findings indicate that the expression of 14-3-3σ may be regulated by other factors than p53.

                To our knowledge, the relationship between levels of 14-3-3σ mRNA and protein expression in vulvar carcinomas has not been studied previously. Gasco et al [25] found a marked reduction or a complete absence of 14-3-3σ mRNA in 20 vulvar carcinomas with CpG methylation. However, in that study no data of corresponding 14-3-3σ protein levels were included [25]. In our work, no significant association was identified between levels of 14-3-3σ mRNA and protein expression. This was consistent with the results in uterine cervical cancer [42] and colon cancer cell lines [24] where expression of 14-3-3σ mRNA did not fully correspond to 14-3-3σ protein expression. These findings indicate that 14-3-3σ expression is also regulated at the post-transcriptional level. There may be modifications of mRNA stability and/or translational efficiency [43], or alternatively, some regulation at the post-translational level may exist [23, 43]. In breast cancer cells post-translational regulation by estrogen-induced zinc finger protein, resulting in 14-3-3σ degradation has been reported [37].

                Conclusion

                Low levels of 14-3-3σ protein expression in 25% of the cases may indicate that 14-3-3σ protein expression may be associated with tumorigenesis in a subset of vulvar squamous cell carcinomas. However 14-3-3σ protein expression was not associated with prognosis.

                Declarations

                Acknowledgements

                We thank Elisabeth Emilsen, Mette Førsund and Ellen Hellesylt for excellent technical support. This project was supported by grants from The Norwegian Cancer Society and Health Region South of Norway. Zhihui Wang is a research fellow of The Norwegian Cancer Society.

                Authors’ Affiliations

                (1)
                Division of Pathology, The Norwegian Radium Hospital, Rikshospitalet University Hospital
                (2)
                Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Medical College of Zhengzhou University
                (3)
                Faculty Division The Norwegian Radium Hospital, Medical Faculty, University of Oslo
                (4)
                Division of Obstetrics and Gynaecology, The Norwegian Radium Hospital, Rikshospitalet University Hospital
                (5)
                Henan Institute of Medical Sciences, Medical College of Zhengzhou University

                References

                1. Coulter J, Gleeson N: Local and regional recurrence of vulval cancer: management dilemmas. Best Pract Res Clin Obstet Gynaecol 2003, 17: 663–681.View ArticlePubMed
                2. Jones RW, Baranyai J, Stables S: Trends in squamous cell carcinoma of the vulva: the influence of vulvar intraepithelial neoplasia. Obstet Gynecol 1997, 90: 448–452.View ArticlePubMed
                3. Messing MJ, Gallup DG: Carcinoma of the vulva in young women. Obstet Gynecol 1995, 86: 51–54.View ArticlePubMed
                4. Tyring SK: Vulvar squamous cell carcinoma: guidelines for early diagnosis and treatment. Am J Obstet Gynecol 2003, 189: S17-S23.View ArticlePubMed
                5. Qi W, Liu X, Qiao D, Martinez JD: Isoform-specific expression of 14–3-3 proteins in human lung cancer tissues. Int J Cancer 2005, 113: 359–363.View ArticlePubMed
                6. Yaffe MB, Rittinger K, Volinia S, Caron PR, Aitken A, Leffers H, et al.: The structural basis for 14–3-3:phosphopeptide binding specificity. cell 1997, 91: 961–971.View ArticlePubMed
                7. Dougherty MK, Morrison DK: Unlocking the code of 14–3-3. J Cell Sci 2004, 117: 1875–1884.View ArticlePubMed
                8. Fu H, Subramanian RR, Masters SC: 14–3-3 proteins: structure, function, and regulation. Annu Rev Pharmacol Toxicol 2000, 40: 617–647.View ArticlePubMed
                9. Mackintosh C: Dynamic interactions between 14–3-3 proteins and phosphoproteins regulate diverse cellular processes. Biochem J 2004, 381: 329–342.View ArticlePubMed
                10. Hermeking H, Lengauer C, Polyak K, He TC, Zhang L, Thiagalingam S, et al.: 14–3-3 sigma is a p53-regulated inhibitor of G2/M progression. Mol cell 1997, 1: 3–11.View ArticlePubMed
                11. Lakin ND, Jackson SP: Regulation of p53 in response to DNA damage. Oncogene 1999, 18: 7644–7655.View ArticlePubMed
                12. Taylor WR, Stark GR: Regulation of the G2/M transition by p53. Oncogene 2001, 20: 1803–1815.View ArticlePubMed
                13. Laronga C, Yang HY, Neal C, Lee MH: Association of the cyclin-dependent kinases and 14–3-3 sigma negatively regulates cell cycle progression. J Biol Chem 2000, 275: 23106–23112.View ArticlePubMed
                14. Chan TA, Hermeking H, Lengauer C, Kinzler KW, Vogelstein B: 14–3-3Sigma is required to prevent mitotic catastrophe after DNA damage. Nature 1999, 401: 616–620.View ArticlePubMed
                15. Ferguson AT, Evron E, Umbricht CB, Pandita TK, Chan TA, Hermeking H, et al.: High frequency of hypermethylation at the 14–3-3 sigma locus leads to gene silencing in breast cancer. Proc Natl Acad Sci USA 2000, 97: 6049–6054.View ArticlePubMed
                16. Iwata N, Yamamoto H, Sasaki S, Itoh F, Suzuki H, Kikuchi T, et al.: Frequent hypermethylation of CpG islands and loss of expression of the 14–3-3 sigma gene in human hepatocellular carcinoma. Oncogene 2000, 19: 5298–5302.View ArticlePubMed
                17. Lodygin D, Yazdi AS, Sander CA, Herzinger T, Hermeking H: Analysis of 14–3-3sigma expression in hyperproliferative skin diseases reveals selective loss associated with CpG-methylation in basal cell carcinoma. Oncogene 2003, 22: 5519–5524.View ArticlePubMed
                18. Lodygin D, Diebold J, Hermeking H: Prostate cancer is characterized by epigenetic silencing of 14–3-3sigma expression. Oncogene 2004, 23: 9034–9041.View ArticlePubMed
                19. Moreira JM, Gromov P, Celis JE: Expression of the tumor suppressor protein 14–3-3 sigma is down-regulated in invasive transitional cell carcinomas of the urinary bladder undergoing epithelial-to-mesenchymal transition. Mol Cell Proteomics 2004, 3: 410–419.View ArticlePubMed
                20. Suzuki H, Itoh F, Toyota M, Kikuchi T, Kakiuchi H, Imai K: Inactivation of the 14–3-3 sigma gene is associated with 5' CpG island hypermethylation in human cancers. Cancer Res 2000, 60: 4353–4357.PubMed
                21. Yatabe Y, Osada H, Tatematsu Y, Mitsudomi T, Takahashi T: Decreased expression of 14–3-3sigma in neuroendocrine tumors is independent of origin and malignant potential. Oncogene 2002, 21: 8310–8319.View ArticlePubMed
                22. Simpson PT, Gale T, Reis-Filho JS, Jones C, Parry S, Steele D, et al.: Distribution and significance of 14–3-3sigma, a novel myoepithelial marker, in normal, benign, and malignant breast tissue. J Pathol 2004, 202: 274–285.View ArticlePubMed
                23. Ito K, Suzuki T, Akahira J, Sakuma M, Saitou S, Okamoto S, et al.: 14–3-3sigma in endometrial cancer – a possible prognostic marker in early-stage cancer. Clin Cancer Res 2005, 11: 7384–7391.View ArticlePubMed
                24. Perathoner A, Pirkebner D, Brandacher G, Spizzo G, Stadlmann S, Obrist P, et al.: 14–3-3sigma expression is an independent prognostic parameter for poor survival in colorectal carcinoma patients. Clin cancer Res 2005, 11: 3274–3279.View ArticlePubMed
                25. Gasco M, Sullivan A, Repellin C, Brooks L, Farrell PJ, Tidy JA, et al.: Coincident inactivation of 14–3-3sigma and p16INK4a is an early event in vulval squamous neoplasia. Oncogene 2002, 21: 1876–1881.View ArticlePubMed
                26. Shepherd JH: Cervical and vulva cancer: changes in FIGO definitions of staging. Br J Obstet Gynaecol 1996, 103: 405–406.View ArticlePubMed
                27. WHO: Pathology and Genetics Tumours of the Breast and Female Genital Organs. World Health Organization Classification of Tumors Lyon: IARC Press 2003, 316–321.
                28. Knopp S, Bjorge T, Nesland JM, Trope C, Scheistroen M, Holm R: p16INK4a and p21Waf1/Cip1 expression correlates with clinical outcome in vulvar carcinomas. Gynecol Oncol 2004, 95: 37–45.View ArticlePubMed
                29. Knopp S, Bjorge T, Nesland JM, Trope C, Holm R: Cyclins D1, D3, E, and A in vulvar carcinoma patients. Gynecol Oncol 2005, 97: 733–739.View ArticlePubMed
                30. Knopp S, Nesland JM, Trope C, Holm R: p14ARF, a prognostic predictor in HPV-negative vulvar carcinoma. Am J Clin Pathol 2006, 126: 266–276.View ArticlePubMed
                31. Scheistroen M, Trope C, Kaern J, Pettersen EO, Alfsen GC, Nesland JM: DNA ploidy and expression of p53 and C-erbB-2 in extramammary Paget's disease of the vulva. Gynecol Oncol 1997, 64: 88–92.View ArticlePubMed
                32. Nakajima T, Shimooka H, Weixa P, Segawa A, Motegi A, Jian Z, et al.: Immunohistochemical demonstration of 14–3-3 sigma protein in normal human tissues and lung cancers, and the preponderance of its strong expression in epithelial cells of squamous cell lineage. Pathol Int 2003, 53: 353–360.View ArticlePubMed
                33. Kurokawa I, Mizutani H, Kusumoto K, Nishijima S, Tsujita-Kyutoku M, Shikata N, et al.: Cytokeratin, filaggrin, and p63 expression in reepithelialization during human cutaneous wound healing. Wound Repair Regen 2006, 14: 38–45.View ArticlePubMed
                34. Ghahary A, Marcoux Y, Karimi-Busheri F, Li Y, Tredget EE, Kilani RT, et al.: Differentiated keratinocyte-releasable stratifin (14–3-3 sigma) stimulates MMP-1 expression in dermal fibroblasts. J Invest Dermatol 2005, 124: 170–177.View ArticlePubMed
                35. Mhawech P, Greloz V, Assaly M, Herrmann F: Immunohistochemical expression of 14–3-3 sigma protein in human urological and gynecological tumors using a multi-tumor microarray analysis. Pathol Int 2005, 55: 77–82.View ArticlePubMed
                36. Bhatia K, Siraj AK, Hussain A, Bu R, Gutierrez MI: The tumor suppressor gene 14–3-3 sigma is commonly methylated in normal and malignant lymphoid cells. Cancer Epidemiol Biomarkers Prev 2003, 12: 165–169.PubMed
                37. Mhawech P: 14–3-3 proteins – an update. Cell Res 2005, 15: 228–236.View ArticlePubMed
                38. van Hemert MJ, Niemantsverdriet M, Schmidt T, Backendorf C, Spaink HP: Isoform-specific differences in rapid nucleocytoplasmic shuttling cause distinct subcellular distributions of 14–3-3 sigma and 14–3-3 zeta. J Cell Sci 2004, 117: 1411–1420.View ArticlePubMed
                39. Piwnica-Worms H: Cell cycle. Fools rush in. Nature 1999, 401: 535–537.View ArticlePubMed
                40. Tanaka K, Hatada T, Kobayashi M, Mohri Y, Tonouchi H, Miki C, et al.: The clinical implication of 14–3-3 sigma expression in primary gastrointestinal malignancy. Int J Oncol 2004, 25: 1591–1597.PubMed
                41. Akahira J, Sugihashi Y, Suzuki T, Ito K, Niikura H, Moriya T, et al.: Decreased expression of 14–3-3 sigma is associated with advanced disease in human epithelial ovarian cancer: its correlation with aberrant DNA methylation. Clin cancer Res 2004, 10: 2687–2693.View ArticlePubMed
                42. Sano T, Shimooka H, Weixa P, Segawa A, Jian Z, Motegi A, et al.: Immunohistochemical expression of 14–3-3 sigma protein in various histological subtypes of uterine cervical cancers. Pathol Int 2004, 54: 743–750.View ArticlePubMed
                43. Audic Y, Hartley RS: Post-transcriptional regulation in cancer. Biol Cell 2004, 96: 479–498.View ArticlePubMed
                44. Pre-publication history

                  1. The pre-publication history for this paper can be accessed here:http://​www.​biomedcentral.​com/​1471-2407/​8/​308/​prepub

                Copyright

                © Wang et al. 2008

                This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://​creativecommons.​org/​licenses/​by/​2.​0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.